David Pinniger, manager of Polar Capital's new Biotechnology fund, casts an eye over a rapidly developing and maturing market.
Biotech funds are becoming increasingly popular after a strong run for the asset class. Last year the NASDAQ biotechnology index rose by 61% compared to the S&P 500’s 26% return. As a result, firms are launching products dedicated to investing in biotech companies to take advantage of opportunities in the sector. Fund manager David Pinniger joined Polar Capital in August 2013 and launched the Polar Capital Biotechnology fund at the start of November that year. He was previously fund manager on the International Biotechnology trust, run by SV Life Sciences. Here he outlines curre...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
